Vol. 23/No. 20

home / publications / oncology-live / vol-23-no-20
William J. Gradishar, MD, and colleagues, explain how treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer

Brittany Lovely
October 19th 2022
Article

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

Pedro C. Barata, MD, MSc

An Influx of Data Expands Options, Improves Treatment for Bladder Cancer

Brittany Lovely
October 18th 2022
Article

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Do-Youn Oh, MD, PhD

Durvalumab Plus Standard-of-Care Chemotherapy Shakes Up First-line Care in Advanced Biliary Tract Cancers

Brittany Lovely
October 17th 2022
Article

Do-Youn Oh, MD, PhD, highlights the nuances of the TOPAZ-1 trial data that signal new pathways forward for investigative efforts in advanced biliary tract cancers.

Maurie Markman, MD

Is Therapeutic Value a New Name for Medical Paternalism?

Maurie Markman, MD
October 14th 2022
ArticleOncology Live®

What is noteworthy is the process whereby this patient employs both objective data and his personal beliefs to declare what he values.